Olof Gidlöf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olof Gidlöf has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
David Erlinge
Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden
11 shared publications- Selvi Celik
Department of Cardiology, Clinical Sciences Lund, Lund University, Lund, Sweden
9 shared publications Björn Olde
Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden
7 shared publications- David Erlinge
Department of Cardiology, Clinical Sciences, Lund University , Lund
6 shared publications - J. Gustav Smith
Göteborgs Universitet
6 shared publications Claes Wahlestedt
The Center for Therapeutic Innovation and Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL
5 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
Age-related changes in spermidine and association with incident heart failure
- 30 September 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
Open AccessAge-related changes in spermidine and association with incident heart failure
- Open Access
- 11 April 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (5) , 2241-2249
Pro-inflammatory LPS drives production and release of the chemokine MCP-1 in human coronary artery smooth muscle cells
The chemokine monocyte chemoattractant protein-1 (MCP-1) plays an important role as chemoattractant for monocytes in atherosclerosis. It is established that MCP-1 is produced by vascular smooth muscle cells, but the underlying mechanisms for its release are not identified. Here, we investigate production and secretion of MCP-1 in primary human coronary artery smooth muscle cells. We demonstrate that the cells express MCP-1 using RT-qPCR, immunocytochemistry and ELISA, and the ELISA analysis shows that they contain high basal levels of MCP-1 compared to human THP-1 monocytes included as positive control representing an immune cell. Immunocytochemistry discloses co-staining for MCP-1 and the ER marker calreticulin, suggesting that they may co-exist. The cellular production of MCP-1 is stimulated by the bacterial endotoxin LPS demonstrated both on mRNA and protein levels. Conditioned medium contains higher amounts of MCP-1 than fresh medium, and pro-inflammatory LPS and TNF-α stimulate release of MCP-1 from the cells. LPS does not enhance the secretion of MCP-1 at an early time point (60 min) neither in the presence nor in the absence of protein synthesis inhibition with cycloheximide, and it has no effect on intracellular [Ca 2+ ] within 0–60 min, suggesting that LPS has no direct effect on the secretory process of MCP-1. We conclude that human coronary artery smooth muscle cells contain high levels of MCP-1, and that pro-inflammatory stimulus triggers secretion of this important chemokine indirectly via activation of MCP-1 production.
- 11 April 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (5) , 2241-2249
Open AccessPro-inflammatory LPS drives production and release of the chemokine MCP-1 in human coronary artery smooth muscle cells
The chemokine monocyte chemoattractant protein-1 (MCP-1) plays an important role as chemoattractant for monocytes in atherosclerosis. It is established that MCP-1 is produced by vascular smooth muscle cells, but the underlying mechanisms for its release are not identified. Here, we investigate production and secretion of MCP-1 in primary human coronary artery smooth muscle cells. We demonstrate that the cells express MCP-1 using RT-qPCR, immunocytochemistry and ELISA, and the ELISA analysis shows that they contain high basal levels of MCP-1 compared to human THP-1 monocytes included as positive control representing an immune cell. Immunocytochemistry discloses co-staining for MCP-1 and the ER marker calreticulin, suggesting that they may co-exist. The cellular production of MCP-1 is stimulated by the bacterial endotoxin LPS demonstrated both on mRNA and protein levels. Conditioned medium contains higher amounts of MCP-1 than fresh medium, and pro-inflammatory LPS and TNF-α stimulate release of MCP-1 from the cells. LPS does not enhance the secretion of MCP-1 at an early time point (60 min) neither in the presence nor in the absence of protein synthesis inhibition with cycloheximide, and it has no effect on intracellular [Ca 2+ ] within 0–60 min, suggesting that LPS has no direct effect on the secretory process of MCP-1. We conclude that human coronary artery smooth muscle cells contain high levels of MCP-1, and that pro-inflammatory stimulus triggers secretion of this important chemokine indirectly via activation of MCP-1 production.
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039248
Metabolite Profiles of Heart Failure, Central Hemodynamic Derangement, and Response to Heart Transplantation
Background: Heart failure (HF) is characterized by hemodynamic derangements that are likely to mediate systemic metabolic perturbations but limited data are available. Plasma metabolite profiling provides opportunities for comprehensive investigation of such perturbations. Here, we aimed to characterize plasma profiles that associate with HF and their relationship with central hemodynamics, symptom burden, and response to restoration of cardiac function by heart transplantation. Methods: Untargeted metabolite profiling was conducted with mass spectrometry in 2 independent case–control samples. Results: In total, 89 of 797 studied metabolites were significantly associated with HF in both cohorts with concordant directionality. Amino acid, carbohydrate, and nucleotide metabolites were enriched for association with HF and were consistently increased in HF cases. A subset of patients with advanced HF subsequently underwent heart transplantation, after which 17 of the 89 metabolites returned significantly toward healthy control levels. These 17 metabolites represent increased catecholamine and heme metabolism, conjugated bile acids, kynurenine pathway mediators, spermidine metabolism, and allantoin, as well as tricarboxylic acid cycle and glycolysis intermediates. Most of these metabolites associated with symptom burden and at least 1 of 12 central hemodynamic parameters, primarily relating to either increased systemic or pulmonary venous congestion, lower cardiac output, or lower left ventricular stroke work. Conclusions: We comprehensively identified metabolite profiles associated with HF and central hemodynamics that reverse by cardiac transplantation. Increased levels of most metabolites also associated with higher symptom burden. Our findings provide perspectives on the metabolic consequences of HF with potential implications for noninvasive monitoring and tailored therapy.
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039248
Open AccessMetabolite Profiles of Heart Failure, Central Hemodynamic Derangement, and Response to Heart Transplantation
Background: Heart failure (HF) is characterized by hemodynamic derangements that are likely to mediate systemic metabolic perturbations but limited data are available. Plasma metabolite profiling provides opportunities for comprehensive investigation of such perturbations. Here, we aimed to characterize plasma profiles that associate with HF and their relationship with central hemodynamics, symptom burden, and response to restoration of cardiac function by heart transplantation. Methods: Untargeted metabolite profiling was conducted with mass spectrometry in 2 independent case–control samples. Results: In total, 89 of 797 studied metabolites were significantly associated with HF in both cohorts with concordant directionality. Amino acid, carbohydrate, and nucleotide metabolites were enriched for association with HF and were consistently increased in HF cases. A subset of patients with advanced HF subsequently underwent heart transplantation, after which 17 of the 89 metabolites returned significantly toward healthy control levels. These 17 metabolites represent increased catecholamine and heme metabolism, conjugated bile acids, kynurenine pathway mediators, spermidine metabolism, and allantoin, as well as tricarboxylic acid cycle and glycolysis intermediates. Most of these metabolites associated with symptom burden and at least 1 of 12 central hemodynamic parameters, primarily relating to either increased systemic or pulmonary venous congestion, lower cardiac output, or lower left ventricular stroke work. Conclusions: We comprehensively identified metabolite profiles associated with HF and central hemodynamics that reverse by cardiac transplantation. Increased levels of most metabolites also associated with higher symptom burden. Our findings provide perspectives on the metabolic consequences of HF with potential implications for noninvasive monitoring and tailored therapy.
- Open Access
- 21 June 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 43, 102105
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca2+-dependent mechanism
- 21 June 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 43, 102105
Open AccessAntimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca2+-dependent mechanism
- Open Access
- 5 March 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (4) , 629-642
Antisense-mediated regulation of exon usage in the elastic spring region of Titin modulates sarcomere function
Aims: Alternative splicing of Titin (TTN) I-band exons produce protein isoforms with variable size and elasticity, but the mechanisms whereby TTN splice factors regulate exon usage and thereby determining cardiomyocyte passive stiffness and diastolic function, is not well understood. Non-coding RNA transcripts from the antisense strand of protein-coding genes have been shown to regulate alternative splicing of the sense gene. The TTN gene locus harbours >80 natural antisense transcripts (NATs) with unknown function in the human heart. The aim of this study was to determine if TTN antisense transcripts play a role in alternative splicing of TTN. Methods and results: RNA-sequencing and RNA in situ hybridization (ISH) of cardiac tissue from heart failure (HF) patients, unused donor hearts, and human iPS-derived cardiomyocytes (iPS-CMs) were used to determine the expression and localization of TTN NATs. Live cell imaging was used to analyse the effect of NATs on sarcomere properties. RNA ISH and immunofluorescence was performed in iPS-CMs to study the interaction between NATs, TTN mRNA, and splice factor protein RBM20. We found that TTN-AS1-276 was the predominant TTN NAT in the human heart and that it was up-regulated in HF. Knockdown of TTN-AS1-276 in human iPS-CMs resulted in decreased interaction between RBM20 and TTN pre-mRNA, decreased TTN I-band exon skipping, and markedly lower expression of the less compliant TTN isoform N2B. The effect on TTN exon usage was independent of sense–antisense exon overlap and polymerase II elongation rate. Furthermore, knockdown resulted in longer sarcomeres with preserved alignment, improved fractional shortening, and relaxation times. Conclusions: We demonstrate a role for TTN-AS1-276 in facilitating alternative splicing of TTN and regulating sarcomere properties. This transcript could constitute a target for improving cardiac passive stiffness and diastolic function in conditions such as heart failure with preserved ejection fraction.
- 5 March 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (4) , 629-642
Open AccessAntisense-mediated regulation of exon usage in the elastic spring region of Titin modulates sarcomere function
Aims: Alternative splicing of Titin (TTN) I-band exons produce protein isoforms with variable size and elasticity, but the mechanisms whereby TTN splice factors regulate exon usage and thereby determining cardiomyocyte passive stiffness and diastolic function, is not well understood. Non-coding RNA transcripts from the antisense strand of protein-coding genes have been shown to regulate alternative splicing of the sense gene. The TTN gene locus harbours >80 natural antisense transcripts (NATs) with unknown function in the human heart. The aim of this study was to determine if TTN antisense transcripts play a role in alternative splicing of TTN. Methods and results: RNA-sequencing and RNA in situ hybridization (ISH) of cardiac tissue from heart failure (HF) patients, unused donor hearts, and human iPS-derived cardiomyocytes (iPS-CMs) were used to determine the expression and localization of TTN NATs. Live cell imaging was used to analyse the effect of NATs on sarcomere properties. RNA ISH and immunofluorescence was performed in iPS-CMs to study the interaction between NATs, TTN mRNA, and splice factor protein RBM20. We found that TTN-AS1-276 was the predominant TTN NAT in the human heart and that it was up-regulated in HF. Knockdown of TTN-AS1-276 in human iPS-CMs resulted in decreased interaction between RBM20 and TTN pre-mRNA, decreased TTN I-band exon skipping, and markedly lower expression of the less compliant TTN isoform N2B. The effect on TTN exon usage was independent of sense–antisense exon overlap and polymerase II elongation rate. Furthermore, knockdown resulted in longer sarcomeres with preserved alignment, improved fractional shortening, and relaxation times. Conclusions: We demonstrate a role for TTN-AS1-276 in facilitating alternative splicing of TTN and regulating sarcomere properties. This transcript could constitute a target for improving cardiac passive stiffness and diastolic function in conditions such as heart failure with preserved ejection fraction.
- Open Access
- 5 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Whole genome sequencing in early onset advanced heart failure
The genetic contributions to early onset heart failure (HF) are incompletely understood. Genetic testing in advanced HF patients undergoing heart transplantation (HTx) may yield clinical benefits, but data is limited. We performed deep-coverage whole genome sequencing (WGS) in 102 Swedish HTx recipients. Gene lists were compiled through a systematic literature review. Variants were prioritized for pathogenicity and classified manually. We also compared polygenic HF risk scores to a population-based cohort. We found a pathogenic (LP/P) variant in 34 individuals (34%). Testing yield was highest in hypertrophic (63% LP/P carriers), dilated (40%) and arrhythmogenic right ventricular (33%) cardiomyopathy and lower in ischemic cardiomyopathy (10%). A family history was more common in LP/P variant carriers than in non-carriers but was present in less than half of carriers (44% vs 13%, P < 0.001), whereas age was similar. Polygenic risk scores were similar in HTx recipients and the population cohort. In conclusion, we observed a high prevalence of pathogenic cardiomyopathy gene variants in individuals with early-onset advanced HF, which could not accurately be ruled out by family history and age. In contrast, we did not observe higher polygenic risk scores in early onset advanced HF cases than in the general population.
- 5 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessWhole genome sequencing in early onset advanced heart failure
The genetic contributions to early onset heart failure (HF) are incompletely understood. Genetic testing in advanced HF patients undergoing heart transplantation (HTx) may yield clinical benefits, but data is limited. We performed deep-coverage whole genome sequencing (WGS) in 102 Swedish HTx recipients. Gene lists were compiled through a systematic literature review. Variants were prioritized for pathogenicity and classified manually. We also compared polygenic HF risk scores to a population-based cohort. We found a pathogenic (LP/P) variant in 34 individuals (34%). Testing yield was highest in hypertrophic (63% LP/P carriers), dilated (40%) and arrhythmogenic right ventricular (33%) cardiomyopathy and lower in ischemic cardiomyopathy (10%). A family history was more common in LP/P variant carriers than in non-carriers but was present in less than half of carriers (44% vs 13%, P < 0.001), whereas age was similar. Polygenic risk scores were similar in HTx recipients and the population cohort. In conclusion, we observed a high prevalence of pathogenic cardiomyopathy gene variants in individuals with early-onset advanced HF, which could not accurately be ruled out by family history and age. In contrast, we did not observe higher polygenic risk scores in early onset advanced HF cases than in the general population.
- Open Access
Cardiomyocyte antisense transcription regulates exon usage in the elastic spring region of Titin to modulate sarcomere function
Background: The spring-like sarcomere protein Titin (TTN) is a key determinant of cardiac passive stiffness and diastolic function. Alternative splicing of TTN I-band exons produce protein isoforms with variable size and elasticity, but the mechanisms regulating TTN exon skipping and isoform composition in the human heart are not well studied. Non-coding RNA transcripts from the antisense strand of protein-coding genes have been shown to regulate alternative splicing of the sense gene. The TTN gene locus harbours >80 antisense transcripts with unknown function in the human heart. The aim of this study was to determine if TTN antisense transcripts play a role in alternative splicing of TTN . Methods: RNA-sequencing and RNA in situ hybridization (ISH) of cardiac tissue from unused organ donor hearts (n=7) and human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) were used to determine the expression and localization of TTN antisense transcripts. The effect of siRNA-mediated knock down of TTN antisense transcripts on TTN exon usage in iPS-CMs was determined using RNA-sequencing. Live cell imaging with sarcomere tracking was used to analyze the effect of antisense transcript knock down on sarcomere length, organization and contraction dynamics. RNA ISH, immunofluorescence and high content microscopy was performed in iPS-CMs to study the interaction between antisense transcripts, TTN mRNA and splice factor protein RBM20. Results: In mapping TTN antisense transcription, we found that TTN-AS1-276 was the predominant transcript in the human heart and that it was mainly localized in cardiomyocyte nuclear chromatin. Knock down of TTN-AS1-276 in human iPS-CMs resulted in decreased interaction between the splicing factor RBM20 and TTN pre-mRNA, decreased TTN I-band exon skipping, and markedly lower expression of the less elastic TTN isoform N2B. The effect on TTN exon usage was independent of sense-antisense exon overlap and polymerase II elongation rate. Furthermore, knockdown resulted in longer sarcomeres with preserved alignment, improved fractional shortening and relaxation times. Conclusions: We demonstrate a role for the cardiac TTN antisense transcript TTN-AS1-276 in facilitating alternative splicing of TTN and regulating sarcomere properties. This transcript could constitute a target for improving cardiac passive stiffness and diastolic function in conditions such as heart failure with preserved ejection fraction.
Open AccessCardiomyocyte antisense transcription regulates exon usage in the elastic spring region of Titin to modulate sarcomere function
Background: The spring-like sarcomere protein Titin (TTN) is a key determinant of cardiac passive stiffness and diastolic function. Alternative splicing of TTN I-band exons produce protein isoforms with variable size and elasticity, but the mechanisms regulating TTN exon skipping and isoform composition in the human heart are not well studied. Non-coding RNA transcripts from the antisense strand of protein-coding genes have been shown to regulate alternative splicing of the sense gene. The TTN gene locus harbours >80 antisense transcripts with unknown function in the human heart. The aim of this study was to determine if TTN antisense transcripts play a role in alternative splicing of TTN . Methods: RNA-sequencing and RNA in situ hybridization (ISH) of cardiac tissue from unused organ donor hearts (n=7) and human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) were used to determine the expression and localization of TTN antisense transcripts. The effect of siRNA-mediated knock down of TTN antisense transcripts on TTN exon usage in iPS-CMs was determined using RNA-sequencing. Live cell imaging with sarcomere tracking was used to analyze the effect of antisense transcript knock down on sarcomere length, organization and contraction dynamics. RNA ISH, immunofluorescence and high content microscopy was performed in iPS-CMs to study the interaction between antisense transcripts, TTN mRNA and splice factor protein RBM20. Results: In mapping TTN antisense transcription, we found that TTN-AS1-276 was the predominant transcript in the human heart and that it was mainly localized in cardiomyocyte nuclear chromatin. Knock down of TTN-AS1-276 in human iPS-CMs resulted in decreased interaction between the splicing factor RBM20 and TTN pre-mRNA, decreased TTN I-band exon skipping, and markedly lower expression of the less elastic TTN isoform N2B. The effect on TTN exon usage was independent of sense-antisense exon overlap and polymerase II elongation rate. Furthermore, knockdown resulted in longer sarcomeres with preserved alignment, improved fractional shortening and relaxation times. Conclusions: We demonstrate a role for the cardiac TTN antisense transcript TTN-AS1-276 in facilitating alternative splicing of TTN and regulating sarcomere properties. This transcript could constitute a target for improving cardiac passive stiffness and diastolic function in conditions such as heart failure with preserved ejection fraction.
- Open Access
- 26 February 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (4) , e23510
Analysis of genetic variant associated with heart failure mortality implicates thymic stromal lymphopoietin as mediator of strain‐induced myocardial fibroblast‐mast cell crosstalk and fibrosis
Heart failure (HF) is a leading cause of death and disability globally. Heritable factors and the extent and pattern of myocardial fibrosis are important determinants of outcomes in patients with HF. In a genome‐wide association study of mortality in HF, we recently identified a genetic polymorphism on chromosome 5q22 associated with HF mortality. Here, we sought to study the mechanisms by which this variant may influence myocardial disease processes. We find that the risk allele is located in an enhancer motif upstream of the TSLP gene (encoding thymic stromal lymphopoietin), conferring increased binding of the transcription factor nescient helix–loop helix 1 (NHLH1) and increased TSLP expression in human heart. Further, we find that increased strain of primary human myocardial fibroblasts results in increased TSLP expression and that the TSLP receptor is expressed in myocardial mast cells in human single nuclei RNA sequence data. Finally, we show that TSLP overexpression induces increased transforming growth factor β expression in myocardial mast cells and tissue fibrosis. Collectively, our findings based on follow‐up of a human genetic finding implicate a novel pathway in myocardial tissue homeostasis and remodeling.
- 26 February 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (4) , e23510
Open AccessAnalysis of genetic variant associated with heart failure mortality implicates thymic stromal lymphopoietin as mediator of strain‐induced myocardial fibroblast‐mast cell crosstalk and fibrosis
Heart failure (HF) is a leading cause of death and disability globally. Heritable factors and the extent and pattern of myocardial fibrosis are important determinants of outcomes in patients with HF. In a genome‐wide association study of mortality in HF, we recently identified a genetic polymorphism on chromosome 5q22 associated with HF mortality. Here, we sought to study the mechanisms by which this variant may influence myocardial disease processes. We find that the risk allele is located in an enhancer motif upstream of the TSLP gene (encoding thymic stromal lymphopoietin), conferring increased binding of the transcription factor nescient helix–loop helix 1 (NHLH1) and increased TSLP expression in human heart. Further, we find that increased strain of primary human myocardial fibroblasts results in increased TSLP expression and that the TSLP receptor is expressed in myocardial mast cells in human single nuclei RNA sequence data. Finally, we show that TSLP overexpression induces increased transforming growth factor β expression in myocardial mast cells and tissue fibrosis. Collectively, our findings based on follow‐up of a human genetic finding implicate a novel pathway in myocardial tissue homeostasis and remodeling.
- Open Access
- 13 October 2021
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 12
Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure
The natriuretic peptide system (NPS) plays a fundamental role in maintaining cardiorenal homeostasis, and its potent filling pressure-regulated diuretic and vasodilatory effects constitute a beneficial compensatory mechanism in heart failure (HF). Leveraging the NPS for therapeutic benefit in HF has been the subject of intense investigation during the last three decades and has ultimately reached widespread clinical use in the form of angiotensin receptor-neprilysin inhibition (ARNi). NPS enhancement via ARNi confers beneficial effects on mortality and hospitalization in HF, but inhibition of neprilysin leads to the accumulation of a number of other vasoactive peptides in the circulation, often resulting in hypotension and raising potential concerns over long-term adverse effects. Moreover, ARNi is less effective in the large group of HF patients with preserved ejection fraction. Alternative approaches for therapeutic augmentation of the NPS with increased specificity and efficacy are therefore warranted, and are now becoming feasible particularly with recent development of RNA therapeutics. In this review, the current state-of-the-art in terms of experimental and clinical strategies for NPS augmentation and their implementation will be reviewed and discussed.
- 13 October 2021
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 12
Open AccessToward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure
The natriuretic peptide system (NPS) plays a fundamental role in maintaining cardiorenal homeostasis, and its potent filling pressure-regulated diuretic and vasodilatory effects constitute a beneficial compensatory mechanism in heart failure (HF). Leveraging the NPS for therapeutic benefit in HF has been the subject of intense investigation during the last three decades and has ultimately reached widespread clinical use in the form of angiotensin receptor-neprilysin inhibition (ARNi). NPS enhancement via ARNi confers beneficial effects on mortality and hospitalization in HF, but inhibition of neprilysin leads to the accumulation of a number of other vasoactive peptides in the circulation, often resulting in hypotension and raising potential concerns over long-term adverse effects. Moreover, ARNi is less effective in the large group of HF patients with preserved ejection fraction. Alternative approaches for therapeutic augmentation of the NPS with increased specificity and efficacy are therefore warranted, and are now becoming feasible particularly with recent development of RNA therapeutics. In this review, the current state-of-the-art in terms of experimental and clinical strategies for NPS augmentation and their implementation will be reviewed and discussed.
- Open Access
- 13 August 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (8) , 1-15
Inhibition of the long non-coding RNA NEAT1 protects cardiomyocytes from hypoxia in vitro via decreased pri-miRNA processing
While restoration of coronary blood flow to the ischemic heart is the most effective strategy for reducing infarct size, reperfusion injury represents a significant limiting factor on clinical outcomes in myocardial infarction patients. Ischemic preconditioning (IPC) has been shown to inhibit reperfusion injury and represents an attractive model for studying cardioprotective signal transduction pathways. Long non-coding RNAs (lncRNAs) are a structurally and functionally heterogenous class of RNA transcripts with unknown roles in IPC-induced cardioprotection. Through microarray-based expression profiling of 31,423 lncRNAs in cardiac tissue from IPC mice, we identified the nuclear transcript Neat1 to be rapidly and robustly decreased in response to IPC. siRNA-mediated knock down of Neat1 reduced apoptosis and necrosis in murine cardiomyocytes (CM) and human iPS-derived CMs in response to prolonged hypoxia and hypoxia-reoxygenation, assessed with Annexin V/propidium iodide-staining, a Caspase 3/7 activity assay, LDH release, and western blot for cleaved Caspase 3. Mechanistically, Neat1 was shown to regulate processing of pro-apoptotic microRNA-22 (miR-22) in murine and human CM nuclei using a luciferase reporter assay. Hypoxia-induced downregulation of Neat1 was shown to result in accumulation of unprocessed pri-miRNA and decreased availability of biologically active miRNA, including miR-22. Addition of exogenous synthetic miR-22 reversed the protective effect of Neat1 knock down in human iPS-CM. In conclusion, we have identified the nuclear lncRNA Neat1 as part of a conserved oxygen-sensitive feedback mechanism by regulation of miRNA processing and a potential target in cardioprotection.
- 13 August 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (8) , 1-15
Open AccessInhibition of the long non-coding RNA NEAT1 protects cardiomyocytes from hypoxia in vitro via decreased pri-miRNA processing
While restoration of coronary blood flow to the ischemic heart is the most effective strategy for reducing infarct size, reperfusion injury represents a significant limiting factor on clinical outcomes in myocardial infarction patients. Ischemic preconditioning (IPC) has been shown to inhibit reperfusion injury and represents an attractive model for studying cardioprotective signal transduction pathways. Long non-coding RNAs (lncRNAs) are a structurally and functionally heterogenous class of RNA transcripts with unknown roles in IPC-induced cardioprotection. Through microarray-based expression profiling of 31,423 lncRNAs in cardiac tissue from IPC mice, we identified the nuclear transcript Neat1 to be rapidly and robustly decreased in response to IPC. siRNA-mediated knock down of Neat1 reduced apoptosis and necrosis in murine cardiomyocytes (CM) and human iPS-derived CMs in response to prolonged hypoxia and hypoxia-reoxygenation, assessed with Annexin V/propidium iodide-staining, a Caspase 3/7 activity assay, LDH release, and western blot for cleaved Caspase 3. Mechanistically, Neat1 was shown to regulate processing of pro-apoptotic microRNA-22 (miR-22) in murine and human CM nuclei using a luciferase reporter assay. Hypoxia-induced downregulation of Neat1 was shown to result in accumulation of unprocessed pri-miRNA and decreased availability of biologically active miRNA, including miR-22. Addition of exogenous synthetic miR-22 reversed the protective effect of Neat1 knock down in human iPS-CM. In conclusion, we have identified the nuclear lncRNA Neat1 as part of a conserved oxygen-sensitive feedback mechanism by regulation of miRNA processing and a potential target in cardioprotection.